| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 83 | 2025 | 837 | 8.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 76 | 2025 | 1523 | 6.980 |
Why?
|
| Heart Failure | 47 | 2025 | 780 | 6.170 |
Why?
|
| Cardiovascular Diseases | 65 | 2025 | 1209 | 5.960 |
Why?
|
| Aged | 208 | 2025 | 11022 | 3.590 |
Why?
|
| Middle Aged | 218 | 2025 | 12726 | 3.540 |
Why?
|
| Diabetes Mellitus | 35 | 2025 | 439 | 3.470 |
Why?
|
| Risk Factors | 134 | 2025 | 4137 | 3.460 |
Why?
|
| Aged, 80 and over | 129 | 2025 | 4157 | 3.190 |
Why?
|
| Female | 232 | 2025 | 21532 | 3.030 |
Why?
|
| Humans | 275 | 2025 | 34562 | 2.850 |
Why?
|
| Prediabetic State | 13 | 2025 | 79 | 2.840 |
Why?
|
| Ethnic Groups | 50 | 2019 | 483 | 2.810 |
Why?
|
| Male | 222 | 2025 | 20740 | 2.790 |
Why?
|
| African Americans | 41 | 2019 | 1435 | 2.750 |
Why?
|
| United States | 103 | 2025 | 4278 | 2.660 |
Why?
|
| Blood Glucose | 30 | 2025 | 529 | 2.610 |
Why?
|
| Insulin Resistance | 20 | 2025 | 488 | 2.590 |
Why?
|
| Hypertension | 25 | 2025 | 1024 | 2.350 |
Why?
|
| Proportional Hazards Models | 36 | 2024 | 804 | 2.200 |
Why?
|
| Body Mass Index | 36 | 2025 | 954 | 2.040 |
Why?
|
| Incidence | 57 | 2025 | 1290 | 2.030 |
Why?
|
| Obesity | 30 | 2025 | 1246 | 1.980 |
Why?
|
| Natriuretic Peptide, Brain | 16 | 2025 | 89 | 1.970 |
Why?
|
| Diabetes Complications | 11 | 2020 | 189 | 1.950 |
Why?
|
| Diabetic Angiopathies | 11 | 2024 | 153 | 1.860 |
Why?
|
| Diet | 14 | 2023 | 418 | 1.760 |
Why?
|
| Postmenopause | 8 | 2025 | 461 | 1.740 |
Why?
|
| Menopause | 6 | 2025 | 111 | 1.620 |
Why?
|
| Blood Pressure | 22 | 2025 | 901 | 1.600 |
Why?
|
| Coronary Artery Disease | 19 | 2025 | 441 | 1.590 |
Why?
|
| Life Style | 19 | 2025 | 418 | 1.590 |
Why?
|
| Peptide Fragments | 13 | 2024 | 430 | 1.530 |
Why?
|
| Risk Assessment | 30 | 2025 | 1508 | 1.530 |
Why?
|
| Stroke Volume | 18 | 2025 | 440 | 1.500 |
Why?
|
| Waist Circumference | 14 | 2025 | 94 | 1.450 |
Why?
|
| Myocardial Infarction | 10 | 2020 | 515 | 1.380 |
Why?
|
| Adult | 60 | 2025 | 10030 | 1.380 |
Why?
|
| European Continental Ancestry Group | 34 | 2018 | 1176 | 1.290 |
Why?
|
| Residence Characteristics | 12 | 2018 | 188 | 1.260 |
Why?
|
| Prospective Studies | 46 | 2025 | 2463 | 1.240 |
Why?
|
| Cohort Studies | 43 | 2025 | 1910 | 1.220 |
Why?
|
| Cross-Sectional Studies | 38 | 2025 | 1607 | 1.200 |
Why?
|
| Lung | 8 | 2025 | 279 | 1.170 |
Why?
|
| Prevalence | 32 | 2025 | 1034 | 1.140 |
Why?
|
| Exercise | 16 | 2025 | 701 | 1.120 |
Why?
|
| Primary Health Care | 7 | 2009 | 240 | 1.120 |
Why?
|
| Coronary Disease | 10 | 2022 | 239 | 1.120 |
Why?
|
| Heart Ventricles | 11 | 2024 | 155 | 1.110 |
Why?
|
| Continental Population Groups | 15 | 2019 | 245 | 1.100 |
Why?
|
| Stroke | 7 | 2022 | 700 | 1.030 |
Why?
|
| Environment Design | 4 | 2019 | 15 | 1.020 |
Why?
|
| Triglycerides | 9 | 2025 | 249 | 1.010 |
Why?
|
| Ventricular Remodeling | 7 | 2024 | 69 | 0.990 |
Why?
|
| Cholesterol | 7 | 2024 | 273 | 0.980 |
Why?
|
| Atrial Fibrillation | 6 | 2023 | 411 | 0.960 |
Why?
|
| Age Factors | 18 | 2025 | 1262 | 0.880 |
Why?
|
| Adipokines | 1 | 2024 | 17 | 0.880 |
Why?
|
| Population Surveillance | 3 | 2025 | 133 | 0.880 |
Why?
|
| Calcinosis | 14 | 2017 | 150 | 0.850 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2024 | 21 | 0.820 |
Why?
|
| Motor Activity | 6 | 2015 | 356 | 0.800 |
Why?
|
| Sex Factors | 15 | 2025 | 708 | 0.800 |
Why?
|
| Overweight | 11 | 2025 | 289 | 0.790 |
Why?
|
| Follow-Up Studies | 27 | 2024 | 2367 | 0.780 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 30 | 0.780 |
Why?
|
| Socioeconomic Factors | 11 | 2019 | 446 | 0.760 |
Why?
|
| Longitudinal Studies | 23 | 2025 | 803 | 0.750 |
Why?
|
| Troponin T | 5 | 2024 | 98 | 0.720 |
Why?
|
| C-Reactive Protein | 9 | 2016 | 248 | 0.710 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2024 | 154 | 0.700 |
Why?
|
| Hispanic Americans | 26 | 2016 | 948 | 0.700 |
Why?
|
| Carotid Arteries | 8 | 2025 | 116 | 0.680 |
Why?
|
| Menopause, Premature | 2 | 2024 | 11 | 0.670 |
Why?
|
| North Carolina | 16 | 2025 | 1613 | 0.670 |
Why?
|
| Ventricular Function, Left | 9 | 2025 | 287 | 0.660 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2017 | 184 | 0.660 |
Why?
|
| Nutrition Surveys | 3 | 2019 | 156 | 0.640 |
Why?
|
| Fasting | 9 | 2019 | 95 | 0.640 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 70 | 0.630 |
Why?
|
| Lipids | 7 | 2025 | 267 | 0.630 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2025 | 1393 | 0.620 |
Why?
|
| Asian Americans | 17 | 2015 | 96 | 0.610 |
Why?
|
| Guideline Adherence | 7 | 2009 | 122 | 0.610 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 183 | 0.610 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2018 | 124 | 0.590 |
Why?
|
| Hyperlipidemias | 3 | 2009 | 61 | 0.590 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 66 | 0.590 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2025 | 988 | 0.580 |
Why?
|
| Multivariate Analysis | 14 | 2018 | 703 | 0.580 |
Why?
|
| Pulmonary Emphysema | 3 | 2025 | 23 | 0.570 |
Why?
|
| Time Factors | 20 | 2025 | 2353 | 0.550 |
Why?
|
| Genome-Wide Association Study | 8 | 2025 | 555 | 0.540 |
Why?
|
| Geographic Information Systems | 2 | 2017 | 15 | 0.540 |
Why?
|
| Coronary Vessels | 5 | 2018 | 180 | 0.530 |
Why?
|
| Body Height | 1 | 2017 | 36 | 0.530 |
Why?
|
| Health Status | 2 | 2017 | 411 | 0.530 |
Why?
|
| Models, Statistical | 2 | 2017 | 193 | 0.530 |
Why?
|
| Adiposity | 10 | 2025 | 204 | 0.520 |
Why?
|
| Evaluation Studies as Topic | 1 | 2017 | 43 | 0.510 |
Why?
|
| Predictive Value of Tests | 16 | 2025 | 939 | 0.510 |
Why?
|
| African Continental Ancestry Group | 12 | 2019 | 367 | 0.510 |
Why?
|
| Calcium | 7 | 2018 | 343 | 0.490 |
Why?
|
| Cholesterol, LDL | 8 | 2018 | 185 | 0.480 |
Why?
|
| Young Adult | 13 | 2023 | 2831 | 0.470 |
Why?
|
| Sleep | 3 | 2025 | 90 | 0.470 |
Why?
|
| Proteomics | 3 | 2025 | 106 | 0.470 |
Why?
|
| Health Status Disparities | 5 | 2022 | 138 | 0.470 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 260 | 0.460 |
Why?
|
| Mass Screening | 2 | 2009 | 269 | 0.450 |
Why?
|
| Inflammation | 5 | 2013 | 557 | 0.450 |
Why?
|
| Prognosis | 16 | 2025 | 1606 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 431 | 0.450 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2016 | 222 | 0.440 |
Why?
|
| Medicare | 4 | 2005 | 224 | 0.430 |
Why?
|
| Metabolomics | 2 | 2025 | 65 | 0.430 |
Why?
|
| Risk Reduction Behavior | 7 | 2017 | 129 | 0.430 |
Why?
|
| Cognition | 4 | 2025 | 576 | 0.420 |
Why?
|
| Albuminuria | 5 | 2017 | 181 | 0.410 |
Why?
|
| Mississippi | 8 | 2025 | 38 | 0.410 |
Why?
|
| Insulin | 6 | 2025 | 394 | 0.410 |
Why?
|
| Glucose Intolerance | 2 | 2012 | 48 | 0.390 |
Why?
|
| Walking | 3 | 2016 | 217 | 0.390 |
Why?
|
| Health Promotion | 2 | 2013 | 264 | 0.390 |
Why?
|
| Electrocardiography | 6 | 2018 | 657 | 0.380 |
Why?
|
| Primary Prevention | 4 | 2019 | 57 | 0.380 |
Why?
|
| Weight Loss | 7 | 2016 | 494 | 0.370 |
Why?
|
| Arteriosclerosis | 4 | 2025 | 150 | 0.370 |
Why?
|
| Cause of Death | 10 | 2019 | 245 | 0.360 |
Why?
|
| Urban Population | 1 | 2013 | 97 | 0.360 |
Why?
|
| Electronic Health Records | 3 | 2020 | 184 | 0.360 |
Why?
|
| Retrospective Studies | 15 | 2023 | 3825 | 0.360 |
Why?
|
| Leptin | 3 | 2024 | 75 | 0.360 |
Why?
|
| Actigraphy | 4 | 2025 | 15 | 0.360 |
Why?
|
| Hypercholesterolemia | 3 | 2010 | 74 | 0.360 |
Why?
|
| Comorbidity | 9 | 2022 | 596 | 0.350 |
Why?
|
| Coronary Angiography | 3 | 2025 | 168 | 0.350 |
Why?
|
| Adiponectin | 3 | 2024 | 111 | 0.350 |
Why?
|
| Algorithms | 1 | 2015 | 561 | 0.350 |
Why?
|
| Food | 1 | 2011 | 49 | 0.350 |
Why?
|
| Cholesterol, HDL | 6 | 2025 | 194 | 0.350 |
Why?
|
| Body Weight | 4 | 2018 | 343 | 0.350 |
Why?
|
| Antihypertensive Agents | 7 | 2019 | 379 | 0.330 |
Why?
|
| Hydrocortisone | 3 | 2018 | 61 | 0.320 |
Why?
|
| Signal Transduction | 2 | 2024 | 771 | 0.320 |
Why?
|
| Managed Care Programs | 3 | 2005 | 43 | 0.320 |
Why?
|
| Social Class | 2 | 2023 | 94 | 0.320 |
Why?
|
| Emigrants and Immigrants | 3 | 2025 | 248 | 0.320 |
Why?
|
| Hospitalization | 6 | 2023 | 500 | 0.310 |
Why?
|
| Feeding Behavior | 6 | 2016 | 168 | 0.310 |
Why?
|
| American Heart Association | 4 | 2019 | 92 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 302 | 0.300 |
Why?
|
| Aldosterone | 3 | 2022 | 27 | 0.300 |
Why?
|
| Chi-Square Distribution | 7 | 2017 | 305 | 0.300 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2020 | 103 | 0.290 |
Why?
|
| Self Care | 2 | 2023 | 144 | 0.290 |
Why?
|
| Morbidity | 5 | 2019 | 103 | 0.290 |
Why?
|
| Tunica Intima | 6 | 2014 | 81 | 0.290 |
Why?
|
| Vital Capacity | 4 | 2024 | 43 | 0.290 |
Why?
|
| Social Environment | 5 | 2018 | 82 | 0.290 |
Why?
|
| Vaccination | 3 | 2025 | 153 | 0.290 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 47 | 0.280 |
Why?
|
| Metabolome | 2 | 2025 | 40 | 0.280 |
Why?
|
| Caregivers | 2 | 2020 | 116 | 0.270 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2013 | 109 | 0.270 |
Why?
|
| Medicaid | 3 | 2005 | 105 | 0.270 |
Why?
|
| Testosterone | 3 | 2025 | 51 | 0.270 |
Why?
|
| Aortic Diseases | 3 | 2017 | 67 | 0.260 |
Why?
|
| Anthropometry | 3 | 2025 | 89 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 2 | 2005 | 76 | 0.260 |
Why?
|
| Physical Fitness | 3 | 2015 | 135 | 0.260 |
Why?
|
| Estradiol | 3 | 2025 | 156 | 0.260 |
Why?
|
| Survival Analysis | 5 | 2016 | 510 | 0.260 |
Why?
|
| Environment | 2 | 2017 | 51 | 0.250 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 27 | 0.250 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2025 | 42 | 0.250 |
Why?
|
| Spirometry | 2 | 2024 | 30 | 0.250 |
Why?
|
| Logistic Models | 8 | 2020 | 808 | 0.240 |
Why?
|
| Forced Expiratory Volume | 3 | 2024 | 92 | 0.240 |
Why?
|
| Fibrosis | 2 | 2024 | 131 | 0.240 |
Why?
|
| Airway Obstruction | 2 | 2024 | 33 | 0.240 |
Why?
|
| Renin | 2 | 2017 | 109 | 0.240 |
Why?
|
| Cerebral Hemorrhage | 2 | 2023 | 72 | 0.240 |
Why?
|
| Aging | 3 | 2025 | 1010 | 0.230 |
Why?
|
| Area Under Curve | 6 | 2017 | 98 | 0.230 |
Why?
|
| Dyslipidemias | 3 | 2013 | 61 | 0.230 |
Why?
|
| Echocardiography | 5 | 2024 | 202 | 0.230 |
Why?
|
| Angina, Unstable | 1 | 2005 | 22 | 0.230 |
Why?
|
| Blood Volume | 1 | 2025 | 9 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 565 | 0.230 |
Why?
|
| Carotid Artery Diseases | 5 | 2024 | 129 | 0.230 |
Why?
|
| Biological Specimen Banks | 1 | 2025 | 11 | 0.230 |
Why?
|
| Tunica Media | 5 | 2014 | 41 | 0.220 |
Why?
|
| Food Supply | 2 | 2016 | 68 | 0.220 |
Why?
|
| Interleukin-6 | 5 | 2015 | 258 | 0.220 |
Why?
|
| Homeostasis | 4 | 2025 | 137 | 0.220 |
Why?
|
| Microvessels | 1 | 2025 | 31 | 0.220 |
Why?
|
| Apolipoprotein C-I | 1 | 2024 | 4 | 0.220 |
Why?
|
| Resistin | 1 | 2024 | 5 | 0.220 |
Why?
|
| Sex Distribution | 4 | 2017 | 194 | 0.220 |
Why?
|
| Sex Characteristics | 4 | 2020 | 182 | 0.220 |
Why?
|
| Genetic Variation | 4 | 2023 | 254 | 0.220 |
Why?
|
| Monocytes | 2 | 2024 | 141 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 1 | 2025 | 99 | 0.210 |
Why?
|
| Diabetic Retinopathy | 2 | 2017 | 72 | 0.210 |
Why?
|
| Severity of Illness Index | 8 | 2025 | 922 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 849 | 0.210 |
Why?
|
| Retinal Artery | 1 | 2024 | 6 | 0.210 |
Why?
|
| Iran | 1 | 2024 | 6 | 0.210 |
Why?
|
| Tissue Donors | 1 | 2025 | 208 | 0.200 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 200 | 0.200 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 112 | 0.200 |
Why?
|
| Linear Models | 7 | 2016 | 465 | 0.200 |
Why?
|
| Research Design | 3 | 2025 | 337 | 0.190 |
Why?
|
| Demography | 2 | 2016 | 112 | 0.190 |
Why?
|
| Exercise Therapy | 1 | 2025 | 283 | 0.190 |
Why?
|
| Dementia | 1 | 2025 | 253 | 0.190 |
Why?
|
| Telephone | 1 | 2023 | 67 | 0.190 |
Why?
|
| Risk | 8 | 2017 | 325 | 0.190 |
Why?
|
| Models, Cardiovascular | 2 | 2020 | 33 | 0.190 |
Why?
|
| Atrial Premature Complexes | 1 | 2022 | 22 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2023 | 585 | 0.190 |
Why?
|
| Glucose Tolerance Test | 4 | 2025 | 141 | 0.180 |
Why?
|
| Sepsis | 1 | 2023 | 167 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 326 | 0.170 |
Why?
|
| Dietary Fats | 2 | 2012 | 115 | 0.170 |
Why?
|
| Polysomnography | 2 | 2018 | 41 | 0.170 |
Why?
|
| Aorta | 2 | 2014 | 139 | 0.170 |
Why?
|
| Reproducibility of Results | 7 | 2025 | 823 | 0.170 |
Why?
|
| Pregnancy | 1 | 2024 | 1069 | 0.160 |
Why?
|
| Privacy | 1 | 2020 | 10 | 0.160 |
Why?
|
| Energy Intake | 2 | 2019 | 138 | 0.160 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 44 | 0.160 |
Why?
|
| Data Collection | 2 | 2019 | 191 | 0.160 |
Why?
|
| Recreation | 1 | 2019 | 12 | 0.150 |
Why?
|
| Hospitals | 1 | 2020 | 105 | 0.150 |
Why?
|
| Social Support | 2 | 2018 | 195 | 0.150 |
Why?
|
| Stress, Psychological | 3 | 2018 | 233 | 0.150 |
Why?
|
| Aortic Valve | 3 | 2011 | 60 | 0.150 |
Why?
|
| Acculturation | 2 | 2016 | 17 | 0.150 |
Why?
|
| Circadian Rhythm | 3 | 2018 | 50 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2020 | 114 | 0.150 |
Why?
|
| Health Behavior | 4 | 2016 | 246 | 0.150 |
Why?
|
| Regression Analysis | 8 | 2012 | 310 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2018 | 199 | 0.140 |
Why?
|
| Disabled Persons | 2 | 2017 | 101 | 0.140 |
Why?
|
| Disease Progression | 6 | 2025 | 634 | 0.140 |
Why?
|
| Smoking | 7 | 2020 | 544 | 0.140 |
Why?
|
| Myocardium | 2 | 2018 | 199 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 35 | 0.140 |
Why?
|
| Models, Theoretical | 2 | 2016 | 146 | 0.140 |
Why?
|
| Disclosure | 1 | 2018 | 33 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2013 | 249 | 0.140 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 37 | 0.140 |
Why?
|
| Hyperglycemia | 2 | 2009 | 88 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 25 | 0.140 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 15 | 0.140 |
Why?
|
| Nutrigenomics | 1 | 2017 | 2 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 548 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 261 | 0.130 |
Why?
|
| Ventricular Function, Right | 2 | 2024 | 20 | 0.130 |
Why?
|
| Glucose | 3 | 2024 | 194 | 0.130 |
Why?
|
| Ankle Brachial Index | 3 | 2018 | 40 | 0.130 |
Why?
|
| Depression | 3 | 2018 | 458 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2025 | 1079 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 58 | 0.130 |
Why?
|
| Counseling | 2 | 2020 | 99 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2017 | 43 | 0.130 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 33 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2024 | 926 | 0.130 |
Why?
|
| Dyspnea | 1 | 2017 | 36 | 0.130 |
Why?
|
| Edema, Cardiac | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 74 | 0.130 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 41 | 0.120 |
Why?
|
| Sleep Deprivation | 1 | 2016 | 12 | 0.120 |
Why?
|
| Heart | 1 | 2018 | 191 | 0.120 |
Why?
|
| Patient Selection | 2 | 2016 | 291 | 0.120 |
Why?
|
| Arizona | 1 | 2016 | 8 | 0.120 |
Why?
|
| Heart Rate | 2 | 2020 | 372 | 0.120 |
Why?
|
| Quality of Life | 4 | 2025 | 1032 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2005 | 67 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 34 | 0.120 |
Why?
|
| Metabolic Diseases | 2 | 2013 | 18 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 261 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 2 | 2013 | 24 | 0.120 |
Why?
|
| Bradycardia | 1 | 2016 | 19 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 168 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2013 | 32 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2005 | 138 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 267 | 0.120 |
Why?
|
| Insulin-Secreting Cells | 1 | 2016 | 56 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2025 | 18 | 0.110 |
Why?
|
| Caloric Restriction | 1 | 2016 | 122 | 0.110 |
Why?
|
| Saliva | 2 | 2013 | 41 | 0.110 |
Why?
|
| Fibrinogen | 3 | 2010 | 69 | 0.110 |
Why?
|
| Vegetables | 2 | 2012 | 41 | 0.110 |
Why?
|
| Air Pollution | 1 | 2015 | 17 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 75 | 0.110 |
Why?
|
| Air Pollutants | 1 | 2015 | 27 | 0.110 |
Why?
|
| Fruit | 2 | 2012 | 57 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 127 | 0.110 |
Why?
|
| Dehydroepiandrosterone | 3 | 2025 | 11 | 0.110 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 28 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2025 | 15 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2016 | 161 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2015 | 107 | 0.110 |
Why?
|
| Acute Disease | 2 | 2025 | 277 | 0.110 |
Why?
|
| Lipoproteins | 1 | 2015 | 99 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 178 | 0.110 |
Why?
|
| Xanthophylls | 1 | 2014 | 3 | 0.110 |
Why?
|
| Lutein | 1 | 2014 | 4 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 91 | 0.110 |
Why?
|
| Health Services | 1 | 2014 | 42 | 0.100 |
Why?
|
| Recurrence | 1 | 2015 | 296 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 83 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2014 | 27 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 70 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2024 | 109 | 0.100 |
Why?
|
| Netherlands | 2 | 2025 | 25 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 126 | 0.100 |
Why?
|
| Age Distribution | 3 | 2016 | 211 | 0.100 |
Why?
|
| Eating | 3 | 2023 | 81 | 0.100 |
Why?
|
| China | 3 | 2024 | 58 | 0.100 |
Why?
|
| Inpatients | 1 | 2013 | 88 | 0.100 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2012 | 2 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2012 | 8 | 0.100 |
Why?
|
| Hyperlipidemia, Familial Combined | 2 | 2010 | 4 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2014 | 198 | 0.090 |
Why?
|
| Calcaneus | 1 | 2012 | 14 | 0.090 |
Why?
|
| Survival Rate | 4 | 2017 | 928 | 0.090 |
Why?
|
| Reference Values | 3 | 2024 | 265 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 74 | 0.090 |
Why?
|
| Diet, Mediterranean | 1 | 2012 | 32 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2012 | 146 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2012 | 14 | 0.090 |
Why?
|
| Vitamins | 2 | 2022 | 75 | 0.090 |
Why?
|
| Heart Atria | 2 | 2022 | 84 | 0.090 |
Why?
|
| Iron, Dietary | 1 | 2012 | 13 | 0.090 |
Why?
|
| Catecholamines | 1 | 2011 | 19 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2012 | 75 | 0.090 |
Why?
|
| Restaurants | 1 | 2011 | 10 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2018 | 19 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2012 | 108 | 0.090 |
Why?
|
| Zinc | 1 | 2012 | 33 | 0.090 |
Why?
|
| Waist-Hip Ratio | 2 | 2025 | 35 | 0.090 |
Why?
|
| Focus Groups | 1 | 2011 | 125 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2015 | 508 | 0.080 |
Why?
|
| Vitamin D | 2 | 2022 | 187 | 0.080 |
Why?
|
| Minority Groups | 2 | 2016 | 90 | 0.080 |
Why?
|
| Bone Density | 1 | 2012 | 209 | 0.080 |
Why?
|
| Individuality | 1 | 2010 | 10 | 0.080 |
Why?
|
| Body Composition | 1 | 2013 | 415 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 614 | 0.080 |
Why?
|
| Phenotype | 2 | 2025 | 657 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2025 | 3623 | 0.080 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 228 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2009 | 366 | 0.080 |
Why?
|
| Computers, Handheld | 1 | 2009 | 15 | 0.070 |
Why?
|
| Chlamydophila Infections | 1 | 2009 | 2 | 0.070 |
Why?
|
| Hepatitis A | 1 | 2009 | 4 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 87 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 9 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 2009 | 14 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2009 | 53 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 168 | 0.070 |
Why?
|
| Creatinine | 3 | 2017 | 206 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 49 | 0.070 |
Why?
|
| Cystatins | 1 | 2008 | 8 | 0.070 |
Why?
|
| Family Practice | 1 | 2009 | 49 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 84 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 39 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2014 | 439 | 0.070 |
Why?
|
| Organ Size | 3 | 2018 | 236 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 108 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 137 | 0.070 |
Why?
|
| Health Personnel | 1 | 2009 | 131 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 274 | 0.070 |
Why?
|
| Reserpine | 1 | 2007 | 4 | 0.070 |
Why?
|
| Goals | 1 | 2007 | 36 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 176 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2008 | 272 | 0.060 |
Why?
|
| Physicians, Family | 1 | 2006 | 16 | 0.060 |
Why?
|
| Professional Practice | 1 | 2006 | 28 | 0.060 |
Why?
|
| Patient Participation | 1 | 2007 | 93 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2006 | 35 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2006 | 59 | 0.060 |
Why?
|
| Heart Valve Diseases | 1 | 2006 | 31 | 0.060 |
Why?
|
| Brain | 2 | 2023 | 1032 | 0.060 |
Why?
|
| Australia | 1 | 2025 | 37 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 20 | 0.060 |
Why?
|
| Southeastern United States | 1 | 2005 | 82 | 0.060 |
Why?
|
| Feces | 1 | 2025 | 43 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 76 | 0.060 |
Why?
|
| Safety | 2 | 2016 | 82 | 0.060 |
Why?
|
| Troponin I | 1 | 2025 | 25 | 0.060 |
Why?
|
| ROC Curve | 2 | 2016 | 176 | 0.060 |
Why?
|
| Adolescent | 3 | 2015 | 3805 | 0.060 |
Why?
|
| Alleles | 2 | 2018 | 261 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2024 | 25 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 193 | 0.050 |
Why?
|
| Inositol | 1 | 2024 | 7 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 105 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2024 | 18 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2025 | 142 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2025 | 177 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2004 | 52 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2004 | 88 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 372 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2024 | 10 | 0.050 |
Why?
|
| Total Quality Management | 1 | 2004 | 19 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2005 | 191 | 0.050 |
Why?
|
| Biological Transport | 1 | 2024 | 76 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 73 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2004 | 51 | 0.050 |
Why?
|
| Indians, North American | 1 | 2004 | 110 | 0.050 |
Why?
|
| Retinal Vessels | 1 | 2024 | 27 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 104 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 315 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 81 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2005 | 214 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2024 | 70 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2015 | 380 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 11 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2023 | 11 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2025 | 268 | 0.050 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2004 | 113 | 0.050 |
Why?
|
| Proteins | 1 | 2004 | 155 | 0.050 |
Why?
|
| Retina | 1 | 2024 | 86 | 0.050 |
Why?
|
| Exercise Test | 1 | 2024 | 247 | 0.050 |
Why?
|
| Genotype | 2 | 2017 | 744 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 43 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 94 | 0.050 |
Why?
|
| Stents | 1 | 2004 | 167 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 4 | 0.050 |
Why?
|
| Melanins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Calcifediol | 1 | 2022 | 10 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2004 | 124 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2022 | 8 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2022 | 23 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2004 | 245 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2023 | 141 | 0.050 |
Why?
|
| Carotid Artery, Internal | 3 | 2007 | 33 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 47 | 0.050 |
Why?
|
| Meat | 2 | 2012 | 17 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2022 | 45 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2002 | 21 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2010 | 417 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 8579 | 0.040 |
Why?
|
| Liver | 1 | 2024 | 513 | 0.040 |
Why?
|
| Cystatin C | 2 | 2012 | 33 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 793 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 2020 | 24 | 0.040 |
Why?
|
| Sex Ratio | 1 | 2018 | 1 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 21 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2019 | 28 | 0.040 |
Why?
|
| Radiography | 2 | 2010 | 397 | 0.040 |
Why?
|
| Patients | 1 | 2018 | 48 | 0.040 |
Why?
|
| Mice | 1 | 2024 | 2720 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 55 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 60 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 318 | 0.030 |
Why?
|
| Child | 1 | 2024 | 2614 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2018 | 28 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 32 | 0.030 |
Why?
|
| Diastole | 1 | 2018 | 100 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 193 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2017 | 39 | 0.030 |
Why?
|
| Systole | 2 | 2009 | 103 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2009 | 120 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 96 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 35 | 0.030 |
Why?
|
| Community Health Services | 1 | 2016 | 50 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2010 | 480 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 197 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 118 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2016 | 51 | 0.030 |
Why?
|
| Nutrition Policy | 1 | 2015 | 35 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 153 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2015 | 6 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2015 | 12 | 0.030 |
Why?
|
| Baltimore | 1 | 2015 | 50 | 0.030 |
Why?
|
| Particle Size | 1 | 2015 | 49 | 0.030 |
Why?
|
| Particulate Matter | 1 | 2015 | 32 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 1 | 2015 | 27 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 7 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 96 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 77 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2014 | 18 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 214 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 76 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 168 | 0.030 |
Why?
|
| Vasodilation | 1 | 2014 | 96 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2014 | 80 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 26 | 0.020 |
Why?
|
| Fishes | 1 | 2012 | 8 | 0.020 |
Why?
|
| Nuts | 1 | 2012 | 5 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Poultry | 1 | 2012 | 27 | 0.020 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 17 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 97 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 22 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 257 | 0.020 |
Why?
|
| Dairy Products | 1 | 2012 | 13 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 56 | 0.020 |
Why?
|
| India | 1 | 2012 | 65 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 207 | 0.020 |
Why?
|
| Cattle | 1 | 2012 | 118 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 55 | 0.020 |
Why?
|
| Vitamin E | 1 | 2012 | 20 | 0.020 |
Why?
|
| Micronutrients | 1 | 2012 | 21 | 0.020 |
Why?
|
| Heme | 1 | 2012 | 61 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 175 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 72 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2012 | 262 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 227 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2010 | 4 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2012 | 222 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 542 | 0.020 |
Why?
|
| Cardiac Volume | 1 | 2009 | 13 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2009 | 37 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 850 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 185 | 0.020 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2009 | 1 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2009 | 3 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 3 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 10 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 8 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2009 | 31 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 202 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 111 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 41 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 136 | 0.020 |
Why?
|
| Education, Medical | 1 | 2008 | 73 | 0.020 |
Why?
|
| Contrast Media | 1 | 2008 | 149 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2009 | 159 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 33 | 0.020 |
Why?
|
| Gender Identity | 1 | 2007 | 28 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 38 | 0.020 |
Why?
|
| Homocysteine | 1 | 2007 | 16 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2007 | 63 | 0.020 |
Why?
|
| Drinking | 1 | 2007 | 10 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 73 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 49 | 0.020 |
Why?
|
| Community Networks | 1 | 2006 | 26 | 0.020 |
Why?
|
| Medical Audit | 1 | 2005 | 16 | 0.010 |
Why?
|
| Motivation | 1 | 2006 | 123 | 0.010 |
Why?
|
| Social Justice | 1 | 2005 | 19 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 2005 | 64 | 0.010 |
Why?
|
| Diuretics | 1 | 2005 | 28 | 0.010 |
Why?
|
| Spironolactone | 1 | 2005 | 11 | 0.010 |
Why?
|
| Crystallization | 1 | 2004 | 18 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 155 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 192 | 0.010 |
Why?
|
| Robotics | 1 | 2004 | 135 | 0.010 |
Why?
|